{"id":1003133,"date":"2026-09-14T07:20:51","date_gmt":"2026-09-14T11:20:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/"},"modified":"2026-09-14T07:20:51","modified_gmt":"2026-09-14T11:20:51","slug":"seaport-therapeutics-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/","title":{"rendered":"Seaport Therapeutics to Participate in September Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Seaport Therapeutics to Participate in September Investor Conferences<\/b><\/p>\n<p>BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.seaporttx.com%2F&amp;esheet=54603179&amp;newsitemid=20260914955578&amp;lan=en-US&amp;anchor=Seaport+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2db4ff44555aa66892355bff709bcc9a\">Seaport Therapeutics, Inc.<\/a> (Nasdaq: SPTX) (\u201cSeaport\u201d or the \u201cCompany\u201d), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Symposium on September 15, 2026.<\/p>\n<p>\nSeaport management will also participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and in one-on-one investor meetings throughout the month. Full details are as follows:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>H.C. Wainwright 28<sup>th<\/sup> Annual Global Investment Conference<\/b>:<b> September 14 \u201316, 2026<\/b> \u2013Seaport management will participate in one-on-one investor meetings.\n<\/li>\n<li><b>Goldman Sachs Life Sciences Symposium: September 15, 2026 \u2013<\/b> Daphne Zohar, Co-Founder and Chief Executive Officer, will deliver a company presentation at 3:50 p.m. ET and participate in the panel discussion, \u201cReimagining Neuroscience: From Scientific Insight to Therapeutic Impact,\u201d at 4:20 p.m. ET.\n<\/li>\n<li><b>Deutsche Bank 2026 Healthcare Summit: September 15 \u201317, 2026<\/b> \u2013 Seaport management will participate in one-on-one investor meetings.\n<\/li>\n<li><b>TD Cowen 6<sup>th<\/sup> Annual Novel Mechanisms in Neuropsychiatry Summit: September 23, 2026 \u2013 <\/b>Members of the management team will participate in a fireside chat at 10:00 a.m. ET.\n<\/li>\n<\/ul>\n<p>\nTo access live webcasts of Seaport\u2019s presentations, please visit the Investors section of the Seaport website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.seaporttx.com%2Fnews-events%2Fevents&amp;esheet=54603179&amp;newsitemid=20260914955578&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.seaporttx.com%2Fnews-events%2Fevents&amp;index=2&amp;md5=39ba7481a20cafcb3d2c33645e31e082\">https:\/\/investors.seaporttx.com\/news-events\/events<\/a>. Archived replays will be available on the website following the event.<\/p>\n<p><b>About Seaport Therapeutics<\/b><\/p>\n<p>\nSeaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and\/or side effects. Seaport applies its proprietary Glyph<sup>TM<\/sup> platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.seaporttx.com%2F&amp;esheet=54603179&amp;newsitemid=20260914955578&amp;lan=en-US&amp;anchor=www.seaporttx.com&amp;index=3&amp;md5=e39a54faad0980635f7683e71638eac5\">www.seaporttx.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260914955578\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260914955578\/en\/<\/a><\/span><\/p>\n<p><b>Seaport Therapeutics<br \/>\n<\/b><br \/><b>Media Contact:<br \/>\n<\/b><br \/>Shannon Costello<br \/>\n<br \/>Vice President, Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:publicrelations@seaporttx.com\">publicrelations@seaporttx.com<\/a><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Adam Bero, Ph.D.<br \/>\n<br \/>Vice President, Head of Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@seaporttx.com\">ir@seaporttx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Mental Health Research Neurology Clinical Trials Health Technology Health Pharmaceutical Other Science Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260914955578\/en\/2630443\/3\/SEAPORT-LOGO.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Seaport Therapeutics to Participate in September Investor Conferences BOSTON&#8211;(BUSINESS WIRE)&#8211;Seaport Therapeutics, Inc. (Nasdaq: SPTX) (\u201cSeaport\u201d or the \u201cCompany\u201d), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Symposium on September 15, 2026. Seaport management will also participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and in one-on-one investor meetings throughout the month. Full details are as follows: H.C. Wainwright 28th Annual Global Investment Conference: September 14 \u201316, 2026 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Seaport Therapeutics to Participate in September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1003133","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Seaport Therapeutics to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seaport Therapeutics to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Seaport Therapeutics to Participate in September Investor Conferences BOSTON&#8211;(BUSINESS WIRE)&#8211;Seaport Therapeutics, Inc. (Nasdaq: SPTX) (\u201cSeaport\u201d or the \u201cCompany\u201d), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Symposium on September 15, 2026. Seaport management will also participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and in one-on-one investor meetings throughout the month. Full details are as follows: H.C. Wainwright 28th Annual Global Investment Conference: September 14 \u201316, 2026 &hellip; Continue reading &quot;Seaport Therapeutics to Participate in September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-14T11:20:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seaport Therapeutics to Participate in September Investor Conferences\",\"datePublished\":\"2026-09-14T11:20:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":435,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/\",\"name\":\"Seaport Therapeutics to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-14T11:20:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seaport-therapeutics-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seaport Therapeutics to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seaport Therapeutics to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Seaport Therapeutics to Participate in September Investor Conferences - Market Newsdesk","og_description":"Seaport Therapeutics to Participate in September Investor Conferences BOSTON&#8211;(BUSINESS WIRE)&#8211;Seaport Therapeutics, Inc. (Nasdaq: SPTX) (\u201cSeaport\u201d or the \u201cCompany\u201d), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Symposium on September 15, 2026. Seaport management will also participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and in one-on-one investor meetings throughout the month. Full details are as follows: H.C. Wainwright 28th Annual Global Investment Conference: September 14 \u201316, 2026 &hellip; Continue reading \"Seaport Therapeutics to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-14T11:20:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seaport Therapeutics to Participate in September Investor Conferences","datePublished":"2026-09-14T11:20:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/"},"wordCount":435,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/","name":"Seaport Therapeutics to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-14T11:20:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260914955578r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seaport-therapeutics-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seaport Therapeutics to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1003133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1003133"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1003133\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1003133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1003133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1003133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}